Related Experiment Video
Updated: Jun 18, 2026
Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent
Published on: May 8, 2017
Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs)
1School of Pharmaceutical Sciences, Shandong University, No. 44 WenhuaXi Road, Ji'nan, 250012, Shandong Province, P.R. China. tjulx2004@sdu.edu.cn
Abstract:
Matrix metalloproteinases (MMPs) belong to a family of closely related calcium- and zinc-dependent endopeptidases involved in the degradation and remodeling of extracellular matrix (ECM) proteins that are associated with the tumorigenic processes. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function. Thus, MMP inhibitors (MMPIs) are expected to be useful chemotherapeutic agents for the treatment of malignant cancer, osteoarthritis, and rheumatoid arthritis. A vast number of small molecular MMPIs have been developed in recent years. Although there have been considerable preclinical and clinical studies on these inhibitors, most of the effective candidates in clinical trials, however, have yielded unsatisfactory results, thus they are as yet unavailable for use as therapeutic drugs. Currently, more efforts have been directed to the design of specific inhibitors towards certain MMP family members for selective usage. This review will focus primarily on an analysis of recent developed MMPIs that have entered preclinical or clinical trials, and recently registered patents with regard to new highly selective MMPIs in USA or patent applications related to the specific inhibitors of MMPs. We also analyze the clinical failure and discuss the possible strategies to best optimize the development of these novel agents.
Insights
Matrix metalloproteinase inhibitors (MMPIs) show promise for cancer and arthritis but face clinical challenges. Research now focuses on developing highly selective MMPIs to improve therapeutic outcomes.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Matrix metalloproteinases (MMPs) are enzymes crucial for extracellular matrix remodeling, implicated in tumorigenesis, invasion, and metastasis.
- MMPs play roles in host defense and normal cellular functions, making them targets for therapeutic intervention.
- MMP inhibitors (MMPIs) are explored for treating cancers, osteoarthritis, and rheumatoid arthritis.
Purpose of the Study:
- To review recent advancements in MMP inhibitor (MMPI) development, focusing on preclinical and clinical trials.
- To analyze newly registered patents for selective MMPIs.
- To discuss clinical failures and propose strategies for optimizing MMPI development.
Main Methods:
- Literature review of recent studies on MMPIs in preclinical and clinical trials.
- Analysis of patent databases for novel selective MMP inhibitors.
- Critical evaluation of clinical trial outcomes and development strategies.
Main Results:
- Numerous small molecular MMPIs have been developed, with many entering preclinical and clinical studies.
- Despite extensive research, most MMPI candidates have shown unsatisfactory clinical results, hindering their therapeutic use.
- Recent efforts concentrate on designing highly selective inhibitors targeting specific MMP family members.
Conclusions:
- The development of effective MMPIs for therapeutic applications remains challenging due to clinical trial failures.
- Increased focus on selectivity for specific MMPs is a key strategy to overcome previous limitations.
- Optimizing the design and development of novel MMPIs is crucial for future therapeutic success.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:23Role of Matrix Metalloproteases in Degradation of ECM
A...